相关实验视频

Updated: Jun 3, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

费德拉提尼布与骨髓纤维化 (FEDORA) 患者的rope-interferon alfa-2b结合:多中心,开放标签,贝叶斯二期试验的研究协议

Graham McIlroy¹, Charlotte Gaskell², Aimee Jackson²

¹Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. g.w.mcilroy.1@bham.ac.uk.

|January 9, 2025

概括

这一II期试验研究了费德拉蒂尼布和rope-interferon alfa-2b用于骨髓纤维化 (MF) 的组合. 费多拉研究旨在确定这种新型组合疗法的安全性和耐受性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

骨髓纤维化 (MF) 是一种严重的克隆性造血干细胞疾病,预后不佳.
JAK2^V617F突变是常见的驱动因素,导致构成性酶激活和疾病进展.
目前的治疗方法旨在控制症状,但对于更深层次的反应和潜在的克隆性缓解,需要组合疗法.

研究的目的:

评估在患有骨髓纤维化症的患者中将费德拉提尼布 (JAK2抑制剂) 与罗佩干扰素α-2b结合使用的耐受性,安全性和活性.
收集证据以确定是否有必要对这种组合进行III期试验.

主要方法:

费多拉试验是一个单臂,多中心,开放标签,贝叶斯二期研究.
它旨在招募30名符合特定风险标准的JAK2^V617F阳性初级或二级MF患者 (中级-1与大至高风险).
将使用患者内部剂量升级方案来确定个性化,可接受的剂量组合.

主要成果:

主要结果是耐受性,定义为缺乏与药物相关的毒性,导致停药,显著的治疗延迟或在前四个月内死亡.
由于试验正在进行中,关于耐受性,安全性和活性的具体结果正在等待.

结论:

费多拉试验采用贝叶斯设计,以有效评估组合疗法.
这项研究的结果将提供关键的数据,关于将费德拉提尼布与rope-interferon alfa-2b结合用于骨髓纤维化治疗的可行性和潜在益处.

关键词:

贝叶斯式设计贝叶斯式设计临床试验临床试验是指临床试验的临床试验.费德拉提尼布的使用方法抑制了JAK2的发生.骨髓纤维化骨髓纤维化第二阶段第二阶段罗佩格干扰素阿尔法-2bbb的使用耐受性耐受性

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...